Why the study?
There have been few reports evaluating the efficacy and safety of trimetazidine in the Indian population.
Does trimetazidine added to standard therapy improve echocardiographic parameters and quality of life in patients with coronary artery disease?
Does trimetazidine added to standard therapy improve echocardiographic parameters and quality of life in patients with coronary artery disease?
Trimetazidine added to standard therapy improves left ventricular function and quality of life in patients with coronary artery disease.
Answers are grounded in this paper and cite their sources.
Should not yet change practice for trimetazidine in CAD; hypothesis-generating and requires randomized confirmation.
There have been few reports on the efficacy and safety of trimetazidine in the Indian population. The study aim is to assess the efficacy and safety of trimetazidine as on add-on with standard therapy in patients with coronary artery disease (CAD) of South India. A 6-month prospective observational comparative study was conducted in 100 patients with CAD. Group A received standard therapy, and group B received standard therapy along with 35 mg of trimetazidine per os (p.o.) twice daily. Quality of life was analyzed using SF-36 questionnaire, and echocardiographic parameters were recorded at the baseline and follow-up in both groups. Laboratory parameters and the safety profile were assessed in both the study groups. The data were analyzed using SPSS, version 17, software. At the follow-up, group B patients showed significant improvement in left ventricular ejection fraction (p-value < 0.001); left ventricular end-diastolic diameter (p-value < 0.01), left ventricular end-systolic diameter (p-value < 0.01), left ventricular end-diastolic volume (p-value < 0.01), left ventricular end-systolic volume (p-value < 0.01), wall motion index score (p-value < 0.05), E/A ratio (p-value < 0.05) compared with group A patients. All eight domains of quality of life were significantly improved in group B with P-value < 0.05, whereas group A showed no difference. No deaths occurred in the study, but few side effects were recorded in both groups. Trimetazidine along with standard therapy improved left ventricular functioning with fewer side effects.
No takes yet. Share an insight, caveat, or question.
Sowjanya et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: